Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG versus NOVOLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG versus NOVOLIN N.
HUMALOG vs NOVOLIN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipocytes, leading to increased glucose uptake and reduced hepatic glucose production.
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 3 or more doses, given within 15 minutes before or immediately after a meal. Typical total daily dose range 0.5-1.0 units/kg/day.
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
None Documented
None Documented
Subcutaneous: 0.5-1.0 hour (insulin lispro); longer with renal impairment (up to 1.5-3 hours).
10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours.
Renal: 60-80% as unchanged drug; biliary/fecal: minor (<10%).
Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%).
Category C
Category C
Insulin
Insulin